Lyell Immunopharma
Last updated: November 11, 2025
CEO - Lynn Seely
Country: USA | Funding: $543M (+)
Founded: 2018
Website: https://lyell.com/
Lyell Immunopharma is developing a CAR-T cell therapy for colorectal cancer. The therapy targets tumors expressing the guanylate cyclase-C (GCC) protein receptor. GCC is expressed in more than 95% of colorectal cancer cases and in most cases of pancreatic adenocarcinoma. Lyell's genetic reprogramming technologies aim to slow T-cell depletion and generate more potent T-cells with enhanced, sustained anti-tumor activity in the immunosuppressive tumor microenvironment.
Founded: 2018
Website: https://lyell.com/
Lyell Immunopharma is developing a CAR-T cell therapy for colorectal cancer. The therapy targets tumors expressing the guanylate cyclase-C (GCC) protein receptor. GCC is expressed in more than 95% of colorectal cancer cases and in most cases of pancreatic adenocarcinoma. Lyell's genetic reprogramming technologies aim to slow T-cell depletion and generate more potent T-cells with enhanced, sustained anti-tumor activity in the immunosuppressive tumor microenvironment.
